What is in your differential diagnosis when considering recurrent C difficile infections? How is a definitive diagnosis made?

The panelist discusses how recurrent Clostridioides difficile infection significantly increases health care costs through prolonged hospitalizations, complex treatments, and elevated medical resource ...

Among 547 episodes of C difficile infection documented in cancer patients in Australia and Spain, 50% were severe, and the 90 ...

XIFAXAN ® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea ...

Highlights:New Research Collaboration with Monash University One proposal will target Antimicrobial Resistant Pathways to develop broad spectrum ...

Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that it has submitted the Clinical Study Report to the U.S. Food ...

Zinplava ™ (bezlotoxumab) injection will be discontinued as of January 31, 2025, according to the Food and Drug Administration’s (FDA) drug shortages tracker.

LAVAL, QC / ACCESS Newswire / January 17, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals, today acknowledged that the Centers for ...

Patients suffering from a recurrent infection with the C difficile bacteria have benefited from a microbiome treatment from Rebiotix. The results from the open label phase 2 trial confirm that ...

The ongoing trial is testing the therapy – RBX2660 – as a treatment for Clostridioides difficile infection or C. diff, a bacterium that causes diarrhoea and inflammation in the colon and is a ...

A fecal transplant could help people whose type 1 diabetes has fouled up their digestive system.Swallowing a handful o ...

To break this link, be conscious of others and prevent microbes from infecting the environment. When sneezing or coughing, ...